We are live on ! Find out more
ECM

Endurant Capital Management Portfolio holdings

AUM $17.4M
1-Year Est. Return 7.38%
This Fund
S&P 500
This Quarter Est. Return
+3.44%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$327M
AUM Growth
-$2.9M
Cap. Flow
-$9.1M
Cap. Flow %
-2.78%
Top 10 Hldgs %
34.51%
Holding
107
New
22
Increased
29
Reduced
23
Closed
32

Top Buys

Rank Stock Value
1
WBA
Walgreens Boots Alliance
WBA
+$10.3M
2
MDT icon
Medtronic
MDT
+$7.09M
3
WMGI
Wright Medical Group Inc
WMGI
+$6.55M
4
AGN
Allergan plc
AGN
+$6.46M
5
MRK icon
Merck
MRK
+$6.16M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$8.12M
2
UHS icon
Universal Health Services
UHS
+$7.89M
3
BIIB icon
Biogen
BIIB
+$7.83M
4
BCR
CR Bard Inc.
BCR
+$5.49M
5
NSTG
NanoString Technologies, Inc.
NSTG
+$4.77M

Sector Composition

Rank Sector Weight
1 Healthcare 86.13%
2 Real Estate 3.64%
3 Financials 2.17%
4 Technology 0.3%
5 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
COR icon
26
Cencora
COR
$60.6B
$5.07M 1.55%
55,240
+21,500
+64% +$1.78M
SHPG
27
DELISTED
Shire pic
SHPG
$5.07M 1.55%
32,696
-22,600
-41% -$3.35M
ELV icon
28
Elevance Health
ELV
$81.5B
$5.07M 1.55%
22,511
-10,300
-31% -$2.19M
VTRS icon
29
Viatris
VTRS
$20.4B
$5.03M 1.54%
118,887
-12,513
-10% -$478K
SYNH
30
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
$4.92M 1.5%
+112,900
New +$5.27M
BIIB icon
31
Biogen
BIIB
$30B
$4.91M 1.5%
15,399
-24,418
-61% -$7.83M
ENTL
32
DELISTED
Entellus Medical, Inc. Common Stock
ENTL
$4.62M 1.41%
189,268
-19,503
-9% -$375K
CLVS
33
DELISTED
Clovis Oncology, Inc.
CLVS
$4.6M 1.41%
67,650
+10,900
+19% +$762K
BDX icon
34
Becton Dickinson
BDX
$45.6B
$4.3M 1.31%
20,572
+6,221
+43% +$1.3M
CELG
35
DELISTED
Celgene Corp
CELG
$3.94M 1.21%
37,800
+21,500
+132% +$2.43M
CVS icon
36
CVS Health
CVS
$133B
$3.86M 1.18%
53,300
+25,800
+94% +$1.88M
FATE icon
37
Fate Therapeutics
FATE
$286M
$3.4M 1.04%
556,679
+283,979
+104% +$1.27M
LH icon
38
Labcorp
LH
$25B
$3.28M 1%
+23,949
New +$3.16M
BAX icon
39
Baxter International
BAX
$13.5B
$3.25M 0.99%
50,249
+29,500
+142% +$1.89M
FOLD
40
DELISTED
Amicus Therapeutics
FOLD
$2.97M 0.91%
+206,400
New +$2.84M
PBYI icon
41
Puma Biotechnology
PBYI
$404M
$2.96M 0.9%
29,900
+8,500
+40% +$951K
KA
42
DELISTED
Kineta, Inc. Common Stock
KA
$2.83M 0.86%
+3,464
New +$1.33M
SYK icon
43
Stryker
SYK
$125B
$2.77M 0.85%
17,867
-7,237
-29% -$1.1M
SRPT icon
44
Sarepta Therapeutics
SRPT
$1.57B
$2.71M 0.83%
48,800
-18,500
-27% -$980K
AERI
45
DELISTED
Aerie Pharmaceuticals
AERI
$2.71M 0.83%
45,366
-11,822
-21% -$717K
MEDP icon
46
Medpace
MEDP
$16.1B
$2.29M 0.7%
+63,100
New +$2.21M
REGN icon
47
Regeneron Pharmaceuticals
REGN
$78.5B
$2.1M 0.64%
+5,600
New +$2.27M
NVRO
48
DELISTED
NEVRO CORP.
NVRO
$1.86M 0.57%
26,961
-12,500
-32% -$1M
HUM icon
49
Humana
HUM
$43.7B
$1.69M 0.52%
+6,800
New +$1.68M
ARA
50
DELISTED
American Renal Associates Holdings, Inc
ARA
$1.55M 0.47%
89,129
-6,827
-7% -$94.2K
1
2
3 4 5

Similar funds

VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
CCMU
Cheyne Capital Management (UK) London, United Kingdom $27.9M AUM 36.14% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
HSCU
Half Sky Capital (UK) London, United Kingdom $30.5M AUM 67.32% 1-Year Est. Return

Endurant Capital Management's Q4 2017 Portfolio in Review

As of Q4 2017, Endurant Capital Management held 107 positions worth $327M, down 0.88% from $330M the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Endurant Capital Management's Q4 2017 filing shows 22 new, 29 increased, 23 reduced and 32 closed positions. Its largest new stake was Merck: 111,193 shares worth $5.97M. The largest sale was Pfizer, an estimated $8.12M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 83% a quarter earlier, followed by Real Estate and Financials.

  • Endurant Capital Management's largest Q4 2017 buy was Merck: 111,193 shares worth $5.97M.
  • Endurant Capital Management added most to Walgreens Boots Alliance in Q4 2017, an estimated $10.3M increase.
  • Endurant Capital Management's biggest Q4 2017 reduction was Biogen, cutting an estimated $7.83M.
  • Endurant Capital Management fully exited Pfizer in Q4 2017, selling an estimated $8.12M.
  • Endurant Capital Management's ten largest holdings make up 35% of its $327M portfolio in Q4 2017.
  • Endurant Capital Management opened 22 new positions and closed 32 in Q4 2017.
  • Endurant Capital Management's portfolio value fell 0.88% quarter-over-quarter to $327M.

Based on Endurant Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.